The Drug Enforcement Administration has increased the production limit of Vyvanse, an ADHD drug made by Takeda Pharmaceutical, and its generic versions by 24% to address an ongoing shortage of the medicines in the U.S.
The government increased the production ceiling of lisdexamfetamine, the active ingredient in Vyvanse, by 6,236 kilograms. More than 1,500 kilograms of the increase is to address increased domestic demand, leaving the remainder for increased foreign demand, the DEA said in a notice posted Sept. 3.
"These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally," the notice said. Bloomberg first reported on the production increase Sept. 3.
The move follows a request from the FDA in July to boost manufacturing quotes to address a shortage of lisdexamfetamine dimesylate capsules and chewable tablets.
ADHD medications have been in shortage since 2022. Adderall went into shortage in October 2022, which led to increased demand and subsequent shortages of alternative therapies, including Vyvanse.